Algernon Pharmaceuticals Management
Management criteria checks 3/4
Algernon Pharmaceuticals' CEO is Chris Moreau, appointed in Mar 2018, has a tenure of 6.17 years. total yearly compensation is CA$544.30K, comprised of 40.4% salary and 59.6% bonuses, including company stock and options. directly owns 4.81% of the company’s shares, worth CA$119.54K. The average tenure of the management team and the board of directors is 3.2 years and 3.6 years respectively.
Key information
Chris Moreau
Chief executive officer
CA$544.3k
Total compensation
| CEO salary percentage | 40.4% |
| CEO tenure | 6.2yrs |
| CEO ownership | 4.8% |
| Management average tenure | 3.2yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Feb 29 2024 | n/a | n/a | -CA$5m |
| Nov 30 2023 | n/a | n/a | -CA$5m |
| Aug 31 2023 | CA$544k | CA$220k | -CA$7m |
| May 31 2023 | n/a | n/a | -CA$6m |
| Feb 28 2023 | n/a | n/a | -CA$6m |
| Nov 30 2022 | n/a | n/a | -CA$7m |
| Aug 31 2022 | CA$576k | CA$220k | -CA$6m |
| May 31 2022 | n/a | n/a | -CA$4m |
| Feb 28 2022 | n/a | n/a | -CA$5m |
| Nov 30 2021 | n/a | n/a | -CA$6m |
| Aug 31 2021 | CA$256k | CA$220k | -CA$8m |
| May 31 2021 | n/a | n/a | -CA$10m |
| Feb 28 2021 | n/a | n/a | -CA$13m |
| Nov 30 2020 | n/a | n/a | -CA$12m |
| Aug 31 2020 | CA$257k | CA$157k | -CA$9m |
| May 31 2020 | n/a | n/a | -CA$6m |
| Feb 29 2020 | n/a | n/a | -CA$2m |
| Nov 30 2019 | n/a | n/a | -CA$2m |
| Aug 31 2019 | CA$108k | CA$108k | -CA$2m |
| May 31 2019 | n/a | n/a | -CA$2m |
| Feb 28 2019 | n/a | n/a | -CA$2m |
| Nov 30 2018 | n/a | n/a | -CA$1m |
| Aug 31 2018 | CA$108k | CA$54k | -CA$938k |
Compensation vs Market: Chris's total compensation ($USD395.61K) is above average for companies of similar size in the Canadian market ($USD174.31K).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Moreau (58 yo)
6.2yrs
Tenure
CA$544,302
Compensation
Mr. Christopher J. Moreau, also known as Chris, has been Chief Executive Officer and Director at Algernon Neuroscience Inc., since December 9, 2022. He has been Chief Executive Officer at Algernon Pharmace...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.2yrs | CA$544.30k | 4.81% CA$ 119.5k | |
| Chief Financial Officer | 2.4yrs | CA$290.10k | 3.76% CA$ 93.3k | |
| Vice President of Research & Operations | 3.2yrs | CA$300.10k | no data |
3.2yrs
Average Tenure
45yo
Average Age
Experienced Management: AGN's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4yrs | CA$544.30k | 4.81% CA$ 119.5k | |
| Independent Chairman of the Board | 2.7yrs | CA$187.17k | 1.78% CA$ 44.1k | |
| Director | 2.3yrs | CA$93.43k | 0.80% CA$ 19.9k | |
| Medical Consultant of Chronic Cough Research Prgm. & Member of Medical and Scientific Advisory Board | 1.3yrs | no data | no data | |
| Independent Director | 8.6yrs | CA$81.94k | 0.53% CA$ 13.2k | |
| Member of Medical & Scientific Advisory Board | no data | no data | no data | |
| Director | 2.7yrs | CA$86.94k | 0.21% CA$ 5.2k | |
| Member of Medical & Scientific Advisory Board | 4.4yrs | no data | no data | |
| Member of Medical & Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Medical & Scientific Advisory Board | 3.6yrs | no data | no data | |
| Member of Medical & Scientific Advisory Board | no data | no data | no data | |
| Member of Medical & Scientific Advisory Board | no data | no data | no data |
3.6yrs
Average Tenure
58yo
Average Age
Experienced Board: AGN's board of directors are considered experienced (3.6 years average tenure).